Fotios Loupakis researcher
Loupakis, Fotios
VIAF ID: 10153470784545080064 (Personal)
Permalink: http://viaf.org/viaf/10153470784545080064
Preferred Forms
- 100 0 _ ‡a Fotios Loupakis ‡c researcher
- 200 _ 1 ‡a Loupakis ‡b , Fotios
- 100 1 _ ‡a Loupakis, Fotios
- 100 1 _ ‡a Loupakis, Fotios
- 100 1 _ ‡a Loupakis, Fotios
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Approfondimenti sul carcinoma colorettale : impiego perioperatorio di bevacizumab e chemioterapia nel paziente con metastasi epatiche, direttamente o potenzialmente resecabili / [Fotios Loupakis, Lisa Salvatore; Alfredo Falcone] | |
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. | |
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan | |
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. | |
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. | |
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | |
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease | |
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. | |
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. | |
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer | |
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis | |
KRAS and BRAF genotyping of synchronous colorectal carcinomas | |
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | |
Liquid biopsy: monitoring cancer-genetics in the blood | |
miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis | |
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer | |
New perspectives for TAS-102: TASK successful? | |
Optimal approach to potentially resectable liver metastases from colorectal cancer | |
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology | |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. | |
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials | |
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. | |
Personalized Management of Colorectal Cancer, [2013]: | |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer | |
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. | |
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients | |
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer | |
The possible role of chemotherapy in antiangiogenic drug resistance. | |
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. | |
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes | |
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? | |
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. | |
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management | |
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients | |
QoL is a cool tool. | |
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. | |
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? | |
Response | |
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer | |
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. | |
The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. | |
The role of tumor angiogenesis as a therapeutic target in colorectal cancer. | |
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies | |
Shared heritability and functional enrichment across six solid cancers | |
Should oncologists be aware in their clinical practice of KRAS molecular analysis? | |
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope | |
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. | |
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer | |
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis | |
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status | |
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. | |
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply | |
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. | |
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. | |
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. | |
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer | |
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity | |
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. | |
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. | |
প্রত্যুত্তর |